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Surgical Treatment of Melanoma 
Scott Hundahl MD, FACS, FSSO* 
"Malignant melanoma writes its message in the skin with 
its own ink ... some see, but do not comprehend. "1 Effective 
treatment of melanoma begins with early recognition. 
Paranoid suspicion of any irregular, pigmented, nodular or 
ulcerated dermal lesion, when coupled with excisional biopsy, 
merits approbation even though many such lesions prove 
benign. 
Biopsy 
In addressing controversial aspects of biopsy, infiltration of 
tissue with local anesthetic around a melanoma jeopardizes 
neither local control nor survivaF. Similarly, a delay of treat-
ment for as much as 4 weeks following even incisional biopsy 
fails to alter local control or prognosis. Shave biopsies of 
melanomas should be avoided, as this technique interferes 
with accurate depth assessment and makes appropriate treat-
ment selection nearly impossible. 
Primary excision 
Historical recommendations concerning margins of exci-
sions in the treatment of primary melanoma seem largely a 
function of surgical tradition rather than science. In collected, 
retrospective series, local recurrence following primary surgi-
cal treatment approximates 3%7 • Presence of risk factors such 
as ulceration of the primary tumor thickness > 4 mm, or loca-
tion in the hand, foot or scalp has been reported as increasing 
local recurrence rates to 10% or more. A prospective study of 
612 patients with non-ulcerated extremity melanoma < 2mm 
in depth, randomized to 1 em versus 3 em excision margins, 
failed to detect any significant difference in local control or sur-
vival. All 4 patients with local recurrence in this study underwent 
excision with 1 em margins, however, and all had melanomas 
thicker than 1 mm; 2 of the 4 died of disease4• Thus, while 1 em 
margins seem fine for < 1 mm thick melanomas, thicker lesions 
may warrant wider excision. An ongoing, prospective, random-
ized intergroup trial, in patients with non-ulcerated melanomas 1 
mm to 4 mm thick, comparing primary excision with 2 em mar-
gins versus 4 em margins, should clarify this issue. 
Tradition dictates primary excision of melanomas en bloc 
with the underlying superficial muscular fascia. Olsen's view 
that resection of fascia might allow dissemination from subder-
mal lymphatics8 prompted some to abandon this tradition. In a 
retrospective, non-randomized comparison, both local recurrence 
and survival in 107 patients with melanoma excised en bloc 
including underlying fascia, closely matched that in 95 patients 
whose underlying fascia was left undisturbed. Fascial excision 
can probably be done safely only in those with thicker 
melanomas. 
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Therapeutic treatment of involved lymph nodes 
In a group of 1,134 patients undergoing therapeutic lym-
phadenectomy for pathologically involved regional lymph 
nodes, Morton and colleagues report 5-, 10-, and 15-year sur-
vival rates of 46%, 41%, and 38% respectively. Multivariate 
analysis of this large group demonstrates that an increasing 
number of involved nodes, greater Breslow thickness of the 
primary, and torso, head or neck location all independently 
decrease survival. Male gender and degree of involved nodal 
enlargement impact the result adversely with borderline statis-
tical significance10• Patients with only 1 positive node enjoy 5-
year survival of 79% 10• Contrary to prevailing opinions that 
patients with involved nodes inevitably harbor occult distant 
metastases, results indicate a surprising proportion can be 
cured by means of a radical regional procedure. Radical lym-
phadenectomy remains the mainstay of treatment in such 
patients. 
Some patients present with regional lymph node involve-
ment without a detectable primary lesion. Overall survival of 
these patients following regional lymphadenectomy approxi-
mates that in patients in whom one can identify a primary 11 • 
Elective lymphadenectomy 
After 2 prospective, randomized trials of elective lym-
phadenectomy versus observation (with therapeutic lym-
phadenectomy if indicated) failed to reveal any significant dif-
ference in 10-year survival, most surgeons abandoned unse-
lective, routine, elective lymphadenectomy in melanoma 
patients12-l4. Balch, analyzing biologic risk of both nodal and 
distant metastases according to thickness of the primary 
lesion, emphasizes that, while benefit seems unlikely in both 
those with relatively thin melanomas, ie low risk of lymph 
node involvement, and in those with advanced, thick 
melanomas >4mm deep, ie high risk of systemic spread-the 
so-called "intermediate subgroup"-at high risk for occult 
nodal disease but at lower risk for occult systemic metastases, 
might indeed benefit from elective lymphadenectomy 15 • 
Analyzing data from both large retrospective, and prospective, 
randomized lymphadenectomy series, Balch identified appar-
ent survival advantage in this variably defined "intermediate 
subgroup"13 • 
To further evaluate elective lymphadenectomy in this sub-
group, patients were added to an ongoing intergroup trial of 1-
mm to 4 mm-thick melanomas, underwent secondary random-
ization: Elective lymphadenectomy versus observation. 
Results of this trial should finally lay to rest any residual con-
troversy concerning elective lymphadenectomy. 
An alternate approach to elective nodal surgery in 
melanoma patients with nonpalpable nodes, pioneered by 
Morton and colleagues, involved selecting patients for lym-
phadenectomy based on results of dye-directed biopsy of sen-
tinel nodes; if such sentinel nodes harbor microscopic disease, 
lymphadenectomy is performed 16• Given the reality of "skip" 
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metastases in melanoma, and the threshold of resolution inherent 
in even the best pathologist's microscopic analysis, having a 
"negative" sentinel node may not guarantee freedom from 
eventual nodal involvement. This intriguing approach certain-
ly merits further study, however. 
Locally advanced melanoma and 
in-transit metastases 
Major amputation in patients with recurrent, locally 
advanced, or in-transit melanoma-usually performed in the 
setting of extensive, necrotic, bleeding or fungating lesions 
with or without in-transit metastases-generates long-term, 
disease-free survival in 20% to 49% of patients, again indicat-
ing that even extensive local-regional disease does not 
inevitably presage systemic involvement17 • 
Hyperthermic, isolated extremity perfusion combined with 
chemotherapy and lymph node dissection (and often surgical 
excision of gross disease) generates long-term survival similar 
to amputation 17-20 • Today most surgeons preferentially treat 
patients presenting with locally advanced disease and in-tran-
sit metastases in this manner. 
Adjuvant hyperthermic limb perfusion 
and elective lymphadenectomy 
Encouraged by the apparent ability of hyperthermic, isolat-
ed-limb perfusion to control locally advanced and in-transit 
disease, Ghussen and colleagues at the University of Cologne 
conducted a prospective, randomized trial of this versus elec-
tive node dissection alone. At almost 6 years median follow-
up, they report 90% 5-year actuarial survival in the perfused 
group versus 62% in the group not perfused (p < 0.01)21 • In 
contrast to others18-20, they report no limb-loss complications 
from the treatment. Results of this treatment remain unsur-
passed by other adjuvant treatment schemes, but have not yet 
been independently confirmed or reproduced by others. 
Surgical resection of isolated metastatic disease 
Overett and Shiu, reporting results of a retrospective study 
of 176 patients undergoing surgical resection of distant 
metastatic deposits of melanoma, found that 33% of such 
patients undergoing complete resection of single-site disease 
survived 5 years. In contrast, those undergoing incomplete 
resection suffered prolonged hospitalization, considerable 
morbidity and negligible benefit, this emphasizes the impor-
tance of mature surgical judgment and judicious selection of 
patients when considering such an approach22• 
Summary 
Surgical resection of disease constitutes the mainstay in 
primary treatment of localized and regional melanoma, offer-
ing long-term survival far in excess of any competing treat-
ment to date. Some highly selected patients can even benefit 
from surgical treatment of isolated distant disease if complete 
resection can be achieved. Adjuvant treatments performed in 
conjunction with surgical procedures such as isolated 
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